These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 37924564)

  • 1. Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence.
    Marchi G; Rajavuori A; Nguyen MTN; Huhtinen K; Oksa S; Hietanen S; Hautaniemi S; Hynninen J; Oikkonen J
    Transl Oncol; 2024 Jan; 39():101814. PubMed ID: 37924564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma.
    Nguyen MTN; Rajavuori A; Huhtinen K; Hietanen S; Hynninen J; Oikkonen J; Hautaniemi S
    Biomed Pharmacother; 2023 Dec; 168():115630. PubMed ID: 37806091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer.
    Chao A; Chen SJ; Chen HC; Tan KT; Hsiao W; Jung SM; Yang LY; Huang KG; Chou HH; Huang HJ; Chang TC; Chao AS; Lee YH; Wu RC; Lai CH
    Biomed J; 2023 Oct; 46(5):100563. PubMed ID: 36208860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.
    Sabatier R; Garnier S; Guille A; Carbuccia N; Pakradouni J; Adelaide J; Provansal M; Cappiello M; Rousseau F; Chaffanet M; Birnbaum D; Mamessier E; Gonçalves A; Bertucci F
    Front Oncol; 2022; 12():946257. PubMed ID: 35965534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.
    Han MR; Lee SH; Park JY; Hong H; Ho JY; Hur SY; Choi YJ
    Cancer Res Treat; 2020 Jul; 52(3):779-788. PubMed ID: 32106643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.
    Schweizer MT; Sivakumar S; Tukachinsky H; Coleman I; De Sarkar N; Yu EY; Konnick EQ; Nelson PS; Pritchard CC; Montgomery B
    JAMA Oncol; 2021 Jun; 7(9):1-5. PubMed ID: 34086042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
    Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
    Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
    Noguchi T; Iwahashi N; Sakai K; Matsuda K; Matsukawa H; Toujima S; Nishio K; Ino K
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer.
    Paracchini L; Mannarino L; Beltrame L; Landoni F; Fruscio R; Grassi T; Dalessandro ML; D'Incalci M; Marchini S
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
    Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
    Front Oncol; 2021; 11():751106. PubMed ID: 35273907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer.
    Oikkonen J; Zhang K; Salminen L; Schulman I; Lavikka K; Andersson N; Ojanperä E; Hietanen S; Grénman S; Lehtonen R; Huhtinen K; Carpén O; Hynninen J; Färkkilä A; Hautaniemi S
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients.
    Chan HT; Nagayama S; Otaki M; Chin YM; Fukunaga Y; Ueno M; Nakamura Y; Low SK
    Front Oncol; 2022; 12():1055968. PubMed ID: 36776372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis.
    He Y; Ma X; Chen K; Liu F; Cai S; Han-Zhang H; Hou T; Xiang J; Peng J
    Cancer Manag Res; 2020; 12():1621-1630. PubMed ID: 32184665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
    Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
    BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring evolutionary trajectories in ovarian cancer patients by longitudinal analysis of ctDNA.
    Kutz O; Drukewitz S; Krüger A; Aust D; William D; Oster S; Schröck E; Baretton G; Link T; Wimberger P; Kuhlmann JD
    Clin Chem Lab Med; 2024 Sep; 62(10):2070-2081. PubMed ID: 38577791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
    Galot R; van Marcke C; Helaers R; Mendola A; Goebbels RM; Caignet X; Ambroise J; Wittouck K; Vikkula M; Limaye N; Machiels JH
    Oral Oncol; 2020 May; 104():104631. PubMed ID: 32169746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.